Launch — Access limited to 250 Members to ensure personalized follow-up quality.
Vitamin B6 (P5P)

Vitamin B6 (P5P)

Pyridoxal-5-phosphate · P5P · Pyridoxine · Pyridoxamine · Pyridoxal

VitaminsGenomic stability

Plasma vitamin B6 levels decline with age, a phenomenon documented independently of dietary intake. This decline accompanies the progressive rise of homocysteine, a sulfur amino acid whose accumulation is associated with cardiovascular and cerebral aging. Vitamin B6 sits at the crossroads of several metabolic pathways whose efficiency wanes over the decades. Its presence in a precision formula aims to support these pathways at a time when the body needs them most.

Last updated: March 24, 2026

Mechanism of Action

Vitamin B6 acts in its active form, pyridoxal-5-phosphate, as a coenzyme in transamination reactions. These reactions allow the body to redistribute amino groups between amino acids, a central process for recycling and producing the molecules tissues require.

It is involved in the synthesis of four major neurotransmitters: serotonin, dopamine, GABA (a calming messenger of the nervous system) and noradrenaline. Each of these syntheses requires a B6-dependent enzyme. Insufficient intake can slow these production pathways.

In the methylation cycle, B6 drives the transsulfuration pathway. This pathway converts homocysteine into cysteine, an amino acid that serves as a precursor to glutathione (the body's primary intracellular antioxidant). The other arm of the cycle, remethylation, depends on vitamins B9 and B12. Covering both pathways simultaneously constitutes a coherent formulation approach.

B6 also participates in hemoglobin synthesis and glycogen metabolism, the energy reserve mobilized by muscles during physical effort.

Key Benefits

  • Strong

    Vitamin B6 contributes to the normal functioning of the nervous system. This effect relies on its role as a coenzyme in the synthesis of serotonin, dopamine, GABA and noradrenaline, four neurotransmitters involved in the regulation of mood, sleep and cognition.

  • Strong

    Vitamin B6 contributes to the reduction of tiredness and fatigue. Several observational studies in adults show that a plasma P5P status below 30 nmol/L is correlated with increased fatigue and impaired cognitive performance.

  • Strong

    Vitamin B6 contributes to normal psychological function. The VITACOG trial showed that combined B6, B9 and B12 supplementation reduces the rate of brain atrophy by 30% in subjects with mild cognitive impairment.

  • Strong

    Vitamin B6 is a cofactor of the homocysteine transsulfuration pathway. A meta-analysis of 72 epidemiological studies established that a 3 µmol/L reduction in homocysteine is associated with a 16% decrease in ischemic heart disease risk and a 24% decrease in stroke risk.

  • Moderate

    Vitamin B6 contributes to the regulation of hormonal activity. It is involved in the conversion of tryptophan to serotonin and then to melatonin, the signal governing the sleep-wake cycle.

  • Moderate

    Vitamin B6 contributes to normal protein and glycogen metabolism. This role is particularly relevant for physically active individuals or those with high protein intake.

  • Moderate

    Vitamin B6 contributes to the normal function of the immune system. Observational data in older adults show that insufficient B6 status is associated with reduced lymphocyte proliferation.

Dosage & Forms

Several forms of vitamin B6 are available for supplementation. Pyridoxine (pyridoxine hydrochloride) is the most common and least expensive form. It must be converted to pyridoxal-5-phosphate (P5P) by the liver before it can be used. Pyridoxamine, naturally present in animal-source foods, follows the same conversion pathway.

P5P is the coenzymatic, directly active form. Singular selects P5P monohydrate to bypass the hepatic conversion step. Some individuals carrying genetic polymorphisms on conversion enzymes (notably pyridoxine 5'-phosphate oxidase) may have reduced conversion capacity. Choosing P5P eliminates this variable.

Recommended dietary allowances for adults range from 1.3 to 1.7 mg/day depending on age and sex. The upper safety limit set by European health authorities is 25 mg/day for pyridoxine. P5P is not subject to the same limit because documented cases of peripheral neuropathy are associated with high doses of pyridoxine (above 100 mg/day for several months), not with P5P.

In the Singular Formula

Inclusion rationale

Vitamin B6 contributes to normal energy metabolism, to the normal functioning of the nervous system, to normal psychological functions, to the reduction of tiredness and fatigue, to normal protein and glycogen metabolism and to the regulation of hormonal activity. Cofactor of over 150 enzymatic reactions, B6 is primarily involved in amino acid metabolism, neurotransmitter synthesis (serotonin, dopamine, GABA, noradrenaline) and hemoglobin synthesis. It also participates in the conversion of tryptophan to niacin (vitamin B3). In the methylation cycle, B6 is the cofactor of the transsulfuration pathway of homocysteine, complementary to the remethylation pathway supported by TMG, vitamin B12 and vitamin B9 (all present in the formula). This coverage of both metabolic pathways of homocysteine is a deliberate formulation choice. The P-5-P (pyridoxal-5-phosphate) form selected is the directly active form, usable by the body without prior hepatic conversion. Conventional forms (pyridoxine, pyridoxamine) must be converted to P-5-P by the liver, a step that may be limited in some individuals with genetic polymorphisms of conversion enzymes.

Selected form

Active form of vitamin B6: pyridoxal-5-phosphate (P5P) monohydrate. Unlike classic forms (pyridoxine, pyridoxamine), P5P is directly usable by the body without prior hepatic conversion. This conversion step can be limiting in certain individuals. P5P serves as a coenzyme in over 150 enzymatic reactions, particularly in amino acid metabolism and neurotransmitter synthesis. Vitamin B6 contributes to normal nervous system function and to the reduction of tiredness and fatigue. Quality: non-GMO, no excipient.

Formula dosage

0 to 19 mg.

Synergies in the formula

Vitamin B6 forms a functional trio with vitamin B9 and vitamin B12 in the methylation cycle. B9 and B12 support the remethylation pathway of homocysteine, while B6 drives the transsulfuration pathway. The simultaneous presence of all three cofactors enables comprehensive management of this metabolic crossroads. Trimethylglycine provides an additional methyl donor to the cycle, offering a remethylation pathway independent of B9. This redundancy strengthens the body's ability to maintain homocysteine levels within the desired range. The transsulfuration pathway supported by B6 produces cysteine. This cysteine joins N-Acetylcysteine and glycine to form glutathione, the body's primary intracellular antioxidant. B6 sits upstream of this synthesis chain. Magnesium is a cofactor of many P5P-dependent enzymes. Adequate magnesium status supports B6 enzymatic activity in transamination and decarboxylation reactions.

Safety & Precautions

Vitamin B6 in P5P form is well tolerated at nutritional doses. Documented adverse effects concern pyridoxine at high doses (above 100 mg/day for several months), which can cause reversible sensory peripheral neuropathy upon discontinuation. This neurotoxicity has not been reported with P5P at supplementation doses.

B6 supplementation is not recommended when taking levodopa alone (without a decarboxylase inhibitor), as B6 can accelerate the peripheral conversion of levodopa and reduce its efficacy. This interaction does not apply to the commonly prescribed levodopa-carbidopa combinations.

Pregnant or breastfeeding women can consume vitamin B6 within recommended intake levels. P5P crosses the placenta and is found in breast milk. Professional advice is recommended for any supplementation beyond reference intakes.

Scientific Studies

AuthorsYearTypeJournal

Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial

The VITACOG trial shows that supplementation with vitamins B6, B9 and B12 reduces the rate of brain atrophy by 30% in subjects with mild cognitive impairment, with an effect proportional to baseline homocysteine levels.

Preventing Alzheimer's disease-related gray matter atrophy by B-vitamin treatment

Secondary analysis of the VITACOG trial showing that B vitamin supplementation reduces gray matter atrophy by up to 53% in vulnerable brain regions in subjects with homocysteine above 13 µmol/L.

Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: the CSPPT randomized clinical trial

This large-scale randomized trial (20,702 participants) shows that homocysteine lowering through folate supplementation reduces first stroke risk by 21% in hypertensive adults.

Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis

Meta-analysis of 30 prospective and retrospective studies establishing that a 3 µmol/L reduction in homocysteine is associated with a 16% decrease in ischemic heart disease risk and a 24% decrease in stroke risk.

Association of vitamin B-6 status with inflammation, oxidative stress, and chronic inflammatory conditions: the Boston Puerto Rican Health Study

Cohort study showing that low vitamin B6 status (plasma PLP) is independently associated with elevated inflammatory markers and increased risk of chronic inflammatory conditions in adults.

Frequently Asked Questions

Vitamin B6 (P5P): Role, Mechanism and Optimal Dosage | Singular